plasmalyte innrennslislyf, lausn
baxter medical ab* - sodium chloride; kalii chloridum; magnesii chloridum; sodium acetate trihydrate; natrii gluconas - innrennslislyf, lausn
pedmarqsi
fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - Öll önnur lækningavörur - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.
phoxilium blóðskilunar-/blóðsíunarlausn 1,2 mmol/l
baxter holding b.v.* - calcium chloride; magnesii chloridum; sodium chloride; sodium hydrogen carbonate; kalii chloridum; disodium phosphate dodecahydrate - blóðskilunar-/blóðsíunarlausn - 1,2 mmol/l
hemosol b0 blóðskilunar-/blóðsíunarlausn
baxter holding b.v.* - sodium hydrogen carbonate; sodium chloride; calcium chloride; magnesii chloridum; acidum lacticum - blóðskilunar-/blóðsíunarlausn
regiocit (prismocit) blóðsíunarlausn 18/140 mmól/l
baxter holding b.v.* - sodium citrate; sodium chloride - blóðsíunarlausn - 18/140 mmól/l
natriumklorid baxter viaflo 9 mg/ml innrennslislyf, lausn 9 mg/ml
baxter medical ab* - sodium chloride - innrennslislyf, lausn - 9 mg/ml
movicol junior neutral mixtúruduft, lausn 6,9 g
norgine healthcare b.v. - macrogol 3350; sodium hydrogen carbonate; kalii chloridum; sodium chloride - mixtúruduft, lausn - 6,9 g
movicol mixtúruduft, lausn 13,8 g
norgine healthcare b.v. - macrogol 3350; sodium chloride; sodium hydrogen carbonate; kalii chloridum - mixtúruduft, lausn - 13,8 g
rescueflow stungulyf/innrennslislyf, lausn 60/75 g/l
oresund pharma aps - dextran 70; sodium chloride - stungulyf/innrennslislyf, lausn - 60/75 g/l
triumeq
viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.